Answers are grounded in this paper and cite their sources.
Background: Nowadays long non-coding RNAs are known as interesting functional part of the transcriptome. LncRNA SNHG6 was reported to be expressed more in breast cancer tissues than non-tumor ones. As a frequent cancer among women, breast cancer treatment needs applied biomarkers for fast prognosis and diagnosis. SNHG6 RNA and its splice variants could be considered as molecular biomarkers for the breast cancer well-timed treatment. Methods: RNA extraction from 35 breast cancer tissues and their relative non-tumor tissues was done and cDNAs of the RNAs were synthesized and then RT-qPCR was performed. Relative expression of SNHG6 202 and 203 was studied in breast cancer samples. Results: The expression patterns of SNHG6 202 and 203 variants were different. Difference in the expression pattern of SNHG6 202 was significantly remarkable in relation to the HER2 status of tumor samples. SNHG6 203 was expressed in tumor and non-tumor tissues differentially and the expression difference was significant. Also, this transcript exhibited significant expression difference in different stages of the studied breast tumor samples. Conclusion: It could be stated that SNHG6 203 transcript might be considered as a prognostic and staging biomarker in breast cancer studies and treatment.
No takes yet. Share an insight, caveat, or question.
Oliayi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: